A biopharma procurement strategy decides who makes your drug substance, API and critical materials, on what terms, and what happens when one of them fails. This guide lays out a five-step framework for sponsors buying CDMO capacity and GMP materials, with FDA data on where risk sits in 2026.
- Procurement in biopharma is a quality decision first. Under 21 CFR 200.10(b), FDA treats a contract facility as an extension of your own.
- Supply is concentrating. FDA's FY2025 quality report shows India's share of API locations for U.S.-based application products rising from 17.9% to 21.2% and China's from 12.2% to 14.7% between 2020 and 2025.
- Segment spend before you source. Treat sole-source APIs and drug substance CDMOs as strategic partnerships, and run routine categories through competitive bids.
- Write risk into the contract. Capacity reservation, change notification, tech transfer rights and data access matter more than unit price.
- Plan for 2026 policy shifts. The BIOSECURE Act, tariffs and DSCSA all change which suppliers are viable over a product's life.
What is a biopharma procurement strategy?
A biopharma procurement strategy is the plan that links a program's CMC timeline to the suppliers who can deliver it. It covers contract manufacturers (CDMOs and CMOs), API and drug substance suppliers, raw materials and excipients, single-use components, testing labs, primary packaging and logistics partners. A good one answers four questions for every critical input: who supplies it, how that supplier was qualified, what the contract obliges them to do, and what the backup plan is.
That makes it different from procurement in most industries. A sponsor cannot switch a validated API source the way a retailer switches a carton vendor. Every change carries comparability work, possible regulatory filings and months of lead time. Procurement choices made in Phase 1 often lock in the commercial supply chain years later, which is why we treat procurement as part of supply chain strategy rather than a purchasing function.
Why procurement is now a quality and supply risk decision
FDA's own data shows how much product quality depends on supplier choice. In FY2025 its drug quality inspection program covered 1,309 inspections, including 61 performed by mutual recognition partners. Only 22% ended with no action indicated; 60% were voluntary action indicated and 18% were official action indicated, the classification that can lead to warning letters or import alerts. Roughly one in five inspected sites, then, had problems serious enough for regulatory action.
At the same time, manufacturing has been shifting. FDA's FY2025 Report on the State of Pharmaceutical Quality tracked API locations for products whose applicant is based in the U.S. India and China gained share between 2020 and 2025, while Europe and the U.S. lost some. FDA attributes the change mainly to new sites being added in those countries, not to closures elsewhere.
Where API for U.S.-based application products is made
Share of API manufacturing locations by region, CY2020 vs CY2025
Concentration matters because shortages tend to start where there is no alternative. According to ASHP and the University of Utah Drug Information Service, active U.S. drug shortages peaked at 323 in Q1 2024 and stood at 227 in Q2 2026, the third straight quarterly increase, and 48% of new 2026 shortages involve sole-source products (AJMC). FDA's root cause analysis of drug shortages reached a related conclusion: the market does not reward manufacturers for mature quality systems, so buyers who choose on price alone pay for it later in disruption.
Quality enforcement has also moved offshore. In FY2024 FDA issued 105 quality-related warning letters to human drug manufacturing sites, the most in five years, and the split between domestic and foreign sites reversed.
FDA drug quality warning letters by site location
Warning letters to human drug manufacturing sites, FY2023 vs FY2024
None of this means foreign suppliers are worse by default. Many of the best API and biologics sites in the world are in India, China, Korea and Europe. It means the qualification and monitoring work has to be real, because FDA will hold the sponsor accountable for what happens at the supplier.
Segment your spend before you source anything
The most common procurement mistake we see at emerging biotechs is running every category through the same process. A sole-source monoclonal antibody drug substance and a box of pipette tips should not get the same RFP template. A segmentation matrix, adapted from the portfolio model Peter Kraljic published in Harvard Business Review in 1983, sorts each category by two factors: how much it affects the program, and how hard it would be to replace.
Biopharma procurement segmentation matrix
Example categories and the sourcing approach each one calls for
Two things change when you sort spend this way. First, the team spends its time where it should: most of the effort goes to the strategic quadrant, which is usually a handful of suppliers. Second, the bottleneck quadrant becomes visible. These are low-cost items that can still stop a batch, such as a custom bag assembly or a chromatography resin with one qualified source. They rarely get attention until a supplier sends a discontinuation notice.
A five-step procurement framework for biopharma sponsors
-
Map demand against the CMC timeline
Start with the program, not the supplier list. Lay out clinical batch needs, process validation (PPQ) timing, launch demand and the realistic range of commercial volumes. For each phase, note when a supplier change would require comparability data or a regulatory filing. That tells you which sourcing decisions must be made early and which can wait. Our process development team often builds this map alongside the tech transfer plan.
-
Segment categories and set a strategy for each
Use the matrix above. For strategic categories, decide now whether you need a second source and by when. For bottleneck items, identify qualified alternates and set safety stock levels. Write the result down: a one-page category strategy for each strategic input saves weeks of debate later.
-
Qualify suppliers on quality before price
Supplier qualification should include an audit, a review of the site's FDA inspection history (the FDA warning letter database is public), and a check of how the supplier handles deviations and change control. For components, 21 CFR 211.84 lets you rely on a supplier's certificate of analysis only if you run at least one specific identity test and validate the supplier's results at appropriate intervals. Our quality assurance and quality control teams build these programs so they hold up in an inspection.
-
Contract for risk, not just price
The quality agreement and the supply agreement do different jobs, and you need both. FDA's guidance on quality agreements for contract manufacturing explains how to define each party's CGMP responsibilities. The supply agreement should cover capacity reservation, forecast and firm-order windows, advance notice of process or site changes, ownership of process data and technology, and your right to transfer the process to another site.
-
Monitor, review and keep a risk management plan
Qualification is not a one-time event. Track on-time delivery, right-first-time batch records, deviation rates and inspection outcomes for every strategic supplier, and review them with the supplier at least quarterly. FDA's draft guidance on risk management plans to mitigate drug shortages and ICH Q9(R1) on quality risk management give a useful structure for documenting those risks and the controls you have in place.
Single source, dual source or regional diversification?
The right sourcing model depends on phase, modality and how much disruption the program can absorb. Most early-stage programs single-source by necessity. The question is when to add a second source and how far away it should be.
| Model | Best fit | Main advantage | Main cost or risk |
|---|---|---|---|
| Single source | Phase 1 to Phase 2, novel modalities, limited capacity in the market | Lowest cost and fastest start; one tech transfer | Any site issue stops supply; weak negotiating position |
| Dual source, same region | Late Phase 3 and commercial products with stable demand | Protects against single-site failure; supports price competition | Second tech transfer and comparability work; regional events can hit both sites |
| Regionally diversified | Commercial products with high patient impact or policy exposure | Protects against regional disruption, tariffs and trade restrictions | Highest cost; more regulatory filings; more complex quality oversight |
For commercial biologics, the second source usually needs to be planned two to three years ahead, because tech transfer, PPQ and the post-approval supplement all take time. Our guides to drug substance supply chains and pharma supply chain fundamentals cover the operational side in more detail.
Policy changes that affect sourcing decisions in 2026
Three policy areas now belong in every strategic sourcing review.
- BIOSECURE Act. Enacted on December 18, 2025 as part of the FY2026 National Defense Authorization Act, it bars federal contracting with companies that use biotechnology equipment or services from designated "biotechnology companies of concern." The initial list is expected around December 2026, with FAR changes to follow, and contracts signed before the prohibition takes effect are grandfathered for five years (Akin Gump summary). Sponsors with federal funding or contracts should map exposure now.
- Tariffs. U.S. trade measures on pharmaceuticals and inputs have changed landed cost calculations for imported API and finished product. See our analysis of U.S. tariffs and pharma supply chains.
- DSCSA. The Drug Supply Chain Security Act requires interoperable, electronic product tracing, so logistics and packaging partners need verified serialization capability. Our guide to qualifying 3PL providers covers the audit steps.
A practical test: for each strategic supplier, ask what would happen to your program if that supplier were unavailable for six months starting tomorrow. If nobody on the team can answer in a sentence, the procurement strategy is not finished.
Common biopharma procurement mistakes
- Choosing a CDMO on quote price alone. A lower batch price is quickly erased by one failed batch or a delayed PPQ campaign.
- Signing a quality agreement without a supply agreement. The quality agreement defines CGMP roles; it does not reserve capacity or protect your process data.
- Ignoring sub-tier suppliers. Your CDMO's resin, media and single-use suppliers are part of your risk profile. Ask for their critical supplier list.
- Waiting until Phase 3 to plan a second source. By then the timeline to add one often overlaps with launch.
- Treating cold chain as a logistics afterthought. For biologics, shipping lanes and packaging need the same qualification as manufacturing. See our post on cold chain risk management.
How DES Pharma supports biopharma procurement
DES Pharma Consulting works with biotech and pharma sponsors on the technical side of procurement: defining requirements, qualifying CDMOs and suppliers, reviewing quality and supply agreements, and building second-source plans. Because our team also covers GxP and GMP quality, process development and analytics, supplier decisions are made with the CMC and regulatory consequences in view. For a wider look at what outside support can cover, see our guide to pharmaceutical consulting and our supply chain and procurement consulting services.
Biopharma procurement strategy: frequently asked questions
What is the difference between procurement and supply chain management in pharma?
Procurement covers selecting, qualifying and contracting suppliers. Supply chain management covers the ongoing flow of materials and product: planning, inventory, manufacturing schedules, distribution and tracing. In biopharma the two overlap heavily, because supplier choices set the limits of what the supply chain can deliver.
When should a biotech start building a procurement strategy?
Before the first CDMO contract, which for most programs means preclinical or IND-enabling work. Early decisions on cell line, process platform and API source tend to carry through to commercial supply, so a basic category plan should exist before Phase 1 batches are ordered.
Does FDA hold the sponsor responsible for CDMO quality problems?
Yes. Under 21 CFR 200.10(b), FDA regards contract facilities as an extension of the manufacturer's own facility. The owner's quality unit remains responsible for approving or rejecting product made by the contractor, which is why quality agreements and supplier oversight matter.
How many suppliers should a biopharma company qualify for a critical API?
There is no fixed number. Early programs usually use one. For commercial products, many sponsors aim for a qualified second source for any input whose loss would stop supply, and choose its location based on regional and policy risk. The decision should come from a documented risk assessment, not a blanket rule.
What should a CDMO supply agreement include?
At minimum: capacity reservation and forecast terms, firm-order windows, pricing and price adjustment rules, advance notice of process, site or sub-supplier changes, ownership of process data and know-how, technology transfer rights, and termination terms that let you move the process if needed.
Build a procurement plan that holds up at launch
Whether you are choosing a first CDMO or adding a second source for a commercial product, DES Pharma can help you qualify suppliers and structure agreements that protect your timeline.
Talk to our teamAbout DES Pharma Consulting. DES Pharma Consulting supports pharmaceutical and biotech companies across CMC, process development, analytical development, quality assurance, regulatory strategy and supply chain. Our consultants bring hands-on industry experience to programs from preclinical development through commercial manufacturing. Learn more about DES Pharma.
Sources
- U.S. FDA, CDER Office of Pharmaceutical Quality. Report on the State of Pharmaceutical Quality, FY2025.
- U.S. FDA, CDER Office of Pharmaceutical Quality. Report on the State of Pharmaceutical Quality, FY2024.
- U.S. FDA. Drug Shortages: Root Causes and Potential Solutions (2019, updated 2020).
- U.S. FDA. Contract Manufacturing Arrangements for Drugs: Quality Agreements, Guidance for Industry (November 2016).
- U.S. FDA. Risk Management Plans to Mitigate the Potential for Drug Shortages, Draft Guidance (May 2022).
- U.S. FDA. Q9(R1) Quality Risk Management (May 2023).
- eCFR. 21 CFR 211.84 and 21 CFR 200.10.
- AJMC. Active US Drug Shortages Rise for Third Straight Quarter (July 2026), reporting ASHP and University of Utah Drug Information Service data.
- Akin Gump. BIOSECURE Act Becomes Law.




